Revelation Biosciences, Inc. REVB
4.12 USD -0.24 (-5.47%)
Nov 12, 2026, 1:56 PM EST
4.15 Day range 4.27
3.08 52-week range 40.60
- YTD
- +28.80%
- 1 year
- +4.87%
News
benzinga.com Revelation Biosciences Q3 EPS $(5.92) Beats $(6.16) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.92) per share which beat the analyst consensus estimate of $(6.16) by 3.9 percent. This is a 88.04 percent increase over losses…
businesswire.com Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat…
benzinga.com Revelation Biosciences Announces 1-For-7 Reverse Stock Split, Effective Oct. 20 Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday's after-market session. The company's market cap stands at $19.8 million. Profusa (NASDAQ:PFSA) stock…- benzinga.com Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury – Study on track to begin later this year –Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat
benzinga.com Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 87.59 percent increase over losses…
benzinga.com Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available…
benzinga.com Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced…
benzinga.com Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
benzinga.com Revelation Biosciences Q1 EPS $(2.71) Misses $(1.55) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.71) per share which missed the analyst consensus estimate of $(1.55) by 74.84 percent. This is a 89.31 percent increase over…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026 - A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS…
- benzinga.com Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over…
- benzinga.com Revelation Biosciences Files Prospectus For The Resale Of 4,272,500 Shares Via Warrants For Potential Proceeds Up To ~$14.7M Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 4,272,500 shares of common stock, par value $0.001 per share, by the…
- benzinga.com Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
- benzinga.com How Do Investors Really Feel About Revelation Biosciences Inc?
- benzinga.com Revelation Biosciences To Implement 1-For-4 Reverse Stock Split, January 28 Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Revelation Biosciences Enters Definitive Agreement For Immediate Exercise Of 13.065M Warrants At $0.86/Share Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED) US stock futures slightly down after 2 days of gains. Trump withdraws tariffs on EU, while Q3 GDP exceeds estimates.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Ericsson Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Revelation Biosciences Reaches Agreement With FDA On Approval Pathway For Gemini To Treat Acute Kidney Injury Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced that the Company has reached…
- benzinga.com Revelation Biosciences Starts GMP Production Of GEMINI, Placebo Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Revelation Biosciences Announces The FDA Has Accepted Its End-Of-Phase 1 Meeting Package For Gemini, Its Acute Kidney Injury Treatment Candidate Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Revelation Biosciences Announces Immediate Exercise Of 4.36M Warrants At $2.20/Share Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Revelation Biosciences Reports Gemini Significantly Reduced Inflammatory Activity And Restored Normal Cellular Response In Stage 3 And 4 CKD Patients Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients.Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Watching Revelation Bios; Zacks Small-Cap Research Gives Stock $21.45 Price Valuation https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08082025_REVB_Sorensen.pdf
- benzinga.com Revelation Biosciences Q2 EPS $(7.01) Misses $(1.49) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the analyst consensus estimate of $(1.49) by 372.05 percent. This is a 97.15 percent increase over…
- benzinga.com 'CDER director Tidmarsh will be acting head of FDA biologics center following Prasad exit'- Endpoints News https://endpoints.news/cder-director-tidmarsh-will-be-acting-head-of-fda-biologics-center-following-prasad-exit/
- benzinga.com Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $21.45/Share Valuation https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07092025_REVB_Sorensen.pdf
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.
benzinga.com Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket 
benzinga.com Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Revelation Biosciences Announces Pricing Of $4M Public Offering Of Up To 14.56M Shares AT An Offering Price Of $1.10/Shr Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session